Objectives: An optimized dosing regimen of the prodrug of colistin, colistin methanesulphonate (CMS), against resistant Pseudomonas aeruginosa is needed to ensure effective bacterial killing. The objectives of this study were to develop a pharmacokinetic (PK)/pharmacodynamic (PD) model that characterizes the time course of the antibacterial activity of colistin against P. aeruginosa in a static in vitro system and to perform simulations of different dosing regimens and dosing algorithms to evaluate the effect of interindividual variability and interoccasion variability in PK on bacterial killing.
Introduction
Pseudomonas aeruginosa is known to possess the capability of developing resistance to multiple antibiotics, be it permanent or temporary (adaptive) resistance. 1 As the bacteria cause secondary infection in long-term disease, e.g. cystic fibrosis, and in immunocompromised and critically ill patients, it poses a serious threat with high morbidity and mortality. In dealing with this resistance-prone Gram-negative bacterium, colistin (polymyxin E) has seen increasing clinical use in the last few years. Colistin is an old antibiotic that did not go through rigorous drug development evaluation when it was introduced, but in recent years there have been several studies on the pharmacokinetic (PK) 2 -6 and pharmacodynamic (PD) 7 -9 properties of this antibiotic to further aid the development of an optimal dosing regimen. 3, 10 An advantage of studying antibiotics is the fact that much information on bacterial killing and growth can be gained from in vitro time -kill curve experiments. In these experiments, bacteria can be tested against single or combinations of antibiotics, across different static or dynamic concentrations, with repeated measurements over time. PK/PD models characterizing the observed emergence of resistance may be developed from in vitro data incorporating the mechanisms of resistance for better representation of the drug effect over time. A mechanism-based PK/PD model developed earlier 11 that considers the co-existence of growing (drug-susceptible) and resting (non-susceptible) bacteria could be further expanded to incorporate resistance. An example is the PK/PD model developed for adaptive resistance of Escherichia coli to gentamicin, 12 which may also be applicable to the time course of killing of P. aeruginosa by colistin. In addition, for colistin, its concentration-and time-dependent disappearance in test tubes 13 (because of adherence to the pipette and tube walls and/or degradation) is an important consideration for understanding the link between concentration and the effect on bacteria.
To increase knowledge of how to dose patients, it is important to establish population PK models built on clinical concentrationtime data that characterize the variability between patients (interindividual variability, IIV) and within patients on different dosing occasions (interoccasion variability, IOV). A population PK model and a PK/PD model based on in vitro data can be combined for predictions and simulations of different dosing regimens that generate concentration -time profiles to drive the PK/PD relationship and bacterial killing. 5, 8, 12, 14 A better understanding of the influence of unexplained and explained variability (e.g. covariates such as weight) can be obtained by comparing bacterial killing with and without these variability components. This approach can help in the development of dosing strategies that not only kill susceptible bacteria but also overcome pre-existing resistance and minimize the development of resistance.
A model that characterizes the PK/PD relationship for colistin in the presence of resistance in vitro would therefore be of value in the evaluation of the efficiency of dosing regimens. In patients, the prodrug colistin methanesulphonate (CMS) has been administered as a flat fixed dose, i.e. the same dose is given to all individuals, with administration typically two or three times daily. 7 Recently, a loading dose of CMS was demonstrated to be needed to quickly achieve therapeutic colistin concentrations, since the formation of colistin from CMS is slow. 4, 5, 9 One study has proposed a dosing algorithm with a weight-based loading dose and creatinine clearance (CL CR )-based maintenance dose, 6 based on identified covariate relationships. However, the unexplained variability in the PK parameters of CMS and colistin remained high (e.g. 84% IIV for CMS clearance). 6 As PK was studied during a single dosing interval, IOV could not be quantified. Unrecognized IOV will be estimated in such situations primarily as increased IIV and can potentially lead to bias in parameter estimates when a large portion of the total variability is IOV. 15 The objectives of this study were to develop a PK/PD model that characterizes the time course of the antibacterial activity of colistin against two different strains of P. aeruginosa in vitro and to perform simulations using a previously developed PK model of CMS and colistin 5 and the PK/PD model developed here, in order to evaluate the effect of IIV and IOV in PK on bacterial killing following different dosing regimens.
Materials and methods

Bacteria and media
In vitro time -kill curve experiments were conducted for 24 h on two strains of P. aeruginosa: wild-type ATCC 27853 (www.atcc.org) and a meropenem-resistant type, ARU552, that had been isolated clinically at the Uppsala Academic Hospital (UAH). 16 MICs of meropenem for the ATCC 27853 strain and the UAH isolate (ARU552) were 0.2 and 16 mg/L, respectively. For colistin, the MICs for the ATCC strain and ARU552 were determined to be 1 and 1.5 mg/L, respectively. The MICs were determined by the Etest method according to the instructions of the manufacturer, bioMé rieux (Marcy-l'É toile, Rhone, France). The bacteria were stored at 2808C and grown at 378C on 5% horse blood agar plates (Columbia Agar Base, Acumedia Manufacturers Inc., Baltimore, MD, USA). 
Antibiotic
The colistin used in the experiments was colistin sulphate purchased from Sigma Aldrich (Schnelldorf, Germany). New stock solution was prepared prior to each experiment by dissolving the antibiotic in sterile distilled water to a concentration of 10 000 mg/L. Serial 2-fold dilutions ranging from 0.25 to 16 mg/L or 0.375 to 24 mg/L colistin were prepared in MH broth.
Time -kill curve experiments
The in vitro time -kill curve experiments were performed without any mechanism for dilution of the colistin concentration, i.e. the colistin concentrations were intended to be constant for the whole 24 h duration of the experiments. All experiments were conducted in 10 mL polypropylene tubes with 4 mL of MH Ca 2+ /Mg 2+ broth. A starting bacterial concentration of 10 6 cfu/mL was added to each tube. Colistin was then added to the tube to achieve a range of different concentrations, both lower and higher than the MIC. The intended colistin concentrations for the ATCC strain were 0.25, 0.5, 1, 2, 4, 8 and 16 mg/L. For P. aeruginosa ARU552, the intended concentrations were 0.375, 0.75, 1.5, 3, 6, 12 and 24 mg/L. For each experiment, a growth control experiment was conducted in which no colistin was added. The tubes were incubated in a temperature-regulated room at 378C. Samples were taken frequently, diluted serially and cultured on two to four agar plates. Samples were taken pre-dose and 0.5, 1, 2, 3, 4, 6, 8 and 24 h after the start of the experiments. The blood agar plates were similarly incubated at 378C and the number of colonies was counted manually after 18 -24 h. For each concentration, the experiments were conducted with two or three replicates on different occasions. The limit of detection (LOD) was 10 cfu/mL.
Measured colistin concentration
Actual colistin concentrations were measured at 0, 8 and 24 h with a previously established analytical method utilizing liquid chromatographytandem mass spectrometry 17 to evaluate potential colistin degradation and binding to the material of the containers used during the experiments. The rate constant of colistin loss (k d ) was calculated for each intended concentration between the different sampling times using log linear regression. The measured concentration and the rate constant were used to derive a predicted colistin concentration at any timepoint during the experiment and this predictive concentration drove the PK/PD model.
Semi-mechanistic PK/PD model building
In the first step, a previously developed semi-mechanistic model describing the development of adaptive resistance of E. coli in the presence of gentamicin 5 was applied to the current data. Different functions (linear, power, exponential and a sigmoid E max function) for describing the concentration -effect relationships and the development of resistance were investigated ( Figure 1 ).
In this model, the basic compartments were drug-susceptible, growing bacteria (S) and non-susceptible, resting bacteria (R) with first-order rate constants for growth (k growth ) and natural death (k death ). 11 The equations below describe the relationship in the absence of antibiotics:
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At the start of the experiments all bacteria were assumed to be in the growing stage (S). When the total number of bacteria in the system increases, a higher fraction of bacteria transfer to a resting stage (R). The rate of transfer is dependent on the rate constant k SR , which is dependent on the number of bacteria, as further described below. This model structure explains why the bacteria, in the absence of antibiotics, will eventually grow and approach a stationary phase in which the total bacterial population is no longer increasing. There is no bacterial growth in the resting stage but the bacteria are assumed to have the same natural death rate (k death ) as bacteria in the growing stage. In the current model, k death was fixed at 0.179 h 21 , a value estimated in a previous study, 11 as there was limited information on this parameter in these experiments.
A proportionality constant is calculated from the difference between the rate constant of growth (k growth ) and the rate constant of death (k death ) divided by the maximum number of bacteria in the stationary phase (B max ). The proportionality constant times the total number of bacteria in the system (S +R) provides the transfer rate constant k SR . As in the previous model, no transfer from the resting to the growing bacterial stage could be estimated based on the experiments (k RS ¼ 0).
The effect of colistin on bacterial killing (k col ) was evaluated to be a linear (g¼1) or power (g=1) function (Equation 3) or a basic E max (g¼1) or sigmoid E max (g=1) function (Equation 4). k col at time 0 is the maximal achievable rate constant of bacterial killing when no resistance has developed. The rate constant of bacterial killing (k drugkill ) is the reduced value of k col caused by the proportion of resistance development (Re ON ) influenced by a power parameter b (Equation 5), which was incorporated into Equation 1 as described in Equation 6 . The drug affected the bacteria only in the growing, susceptible stage (S).
E max is the rate constant for the maximal achievable kill by colistin in the absence of adaptive resistance while EC 50 is the antibiotic concentration that results in 50% of the maximum kill rate constant at any timepoint. The presence of colistin initiated resistance development, i.e. initially the whole fraction of a hypothetical amount was in a compartment for no adaptive resistance, Re OFF , and upon colistin exposure the amount started to transfer to a compartment for resistance being present, Re ON . In the final model k col was directly reduced from its initial value by the amount in Re ON , and the actual rate constant affecting the bacteria was described as k drugkill (Equation 5, Figure 1 ). The transfers of the amount describing adaptive resistance are described in Equations 8 and 9. k on and k off describe the rate of development and reversal of adaptive resistance, respectively. k on was dependent on colistin concentration by a sigmoidal E max function with a Hill factor d (Equation 7). k onmax is the maximal achievable resistance rate constant in the presence of colistin while C on50 is the antibiotic concentration that results in 50% of k onmax .
In addition to variants of the model described above, two other structural models for resistance were evaluated: (i) a function whereby EC 50 of colistin at the initiation of the experiment [EC 50(0) ] increases with time and colistin concentration, EC 50 ¼EC 50(0) ×(12e 2k×C×t ); 18 and (ii) a compensatory mutation function. 19 
Data analysis
The bacterial count data were transformed into natural logarithms and all data were fitted simultaneously. To avoid the potential bias that may be introduced when modelling average data, all plates with a detectable number of bacteria were included in the data analysis. There was therefore generally more than one bacterial count determination per sampling timepoint and experiment included in the estimation. The residual error 
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Resistance development Bacterial system Figure 1 . Schematic illustration of the final PK/PD model. The bacteria are either in a growing and drug-susceptible compartment (S) or in a resting and drug-non-susceptible compartment (R). The bacteria multiply with a first-order rate constant in the susceptible compartment (k growth ) and all bacteria have a first-order natural death rate (k death ). The total bacterial content in the system (S+R) stimulates the transfer, determined by a rate constant (k SR ), from the growing stage into the resting stage. The colistin compartment (Col), with a first-order elimination rate (k e ), drove the killing of the bacteria. In model development, k e was set to the disappearance rate constants for colistin determined from the in vitro experiments and in the simulations this compartment was exchanged with the PK compartment for colistin. The PD model included a function with a rate constant for development (k on ) of resistance (Re ON ) from a non-resistant state (Re OFF ), which was dependent on colistin concentration, and a rate constant for return to susceptibility (k off ). k col was a basic E max model for ATCC 27853 (E max ×C col )/(EC 50 +C col ) and a linear function for ARU552 (slope×C col ) (C col is colistin concentration). An increased amount (fraction) in Re ON resulted in a reduction of the maximum bacterial killing by colistin. The two CMS compartments, CMS 1 and CMS 2 , were only utilized during predictions using the PK model, where the dose was introduced into CMS 1 .
was split into two different components: one consistent difference common to all replicates at the same timepoint and experiment (RES) and one replicate-specific difference (RRES) 20 to avoid bias between the replicates due to correlations. For timepoints at which all dilutions had bacterial counts below the LOD, the probability of the observation being below the LOD was estimated using the M3 method. 21, 22 The mean tendencies in the population, i.e. the typical parameter values, were estimated along with random effects described by the residual errors. It was assumed that the variability between the experiments was insignificant and therefore no inter-experiment variability was estimated. Model performance was assessed by the evaluation of diagnostic plots and the objective function value (OFV). In order to discriminate between nested models, the difference in OFV (22 log likelihood) was used. The more complex model was selected when the reduction in OFV was at least 10.83 (P,0.001 for 1 degree of freedom). The model was also evaluated by performing visual predictive checks (VPCs) 23 with stratification on the type of experiment and on the colistin concentration, i.e. all observations from duplicate experiments and all measurements were plotted and overlaid with the median and 80% prediction intervals (10th and 90th percentiles) obtained by simulating 1000 replicates of the original dataset. Log likelihood profiling was utilized to obtain standard errors of the parameters.
Simulations for assessment of patient population variability
The final parameter estimates from the current colistin PK/PD model for the ATCC strain and a previously developed PK model for CMS and colistin in critically ill patients 5 was used to simulate the drug concentration and bacteria -time profiles, including IIV and/or IOV. The PK model consisted of two compartments for CMS and one compartment for the formed colistin. CMS clearance (CL CMS ) was 13. CMS loading doses of 6, 9 or 12 million units (MU) [180, 270 and 360 mg colistin base activity (CBA), respectively] followed by maintenance dosing of 4.5 MU CMS (135 mg CBA) every 12 h, administered as 15 min infusions, were evaluated following inclusion of both IIV and IOV, or IIV only or IOV only. The IIV and IOV values were simulated for three different scenarios: (i) all variability terms included, as in the developed PK model; 5 (ii) variability for CMS or colistin only; and (iii) variability for CL CMS or CL Col only. For each scenario and dosing schedule, 1000 patients were simulated. Comparisons of the variability (the 90% prediction interval) were made for the measured variables colistin concentration and log bacterial count. The percentage of simulated patients who achieved 3 log bacterial killing at a certain timepoint (e.g. 12 h) was also computed.
Simulations for comparison of dosing algorithm
In order to evaluate the performance of different dosing schedules, the PK/PD model for the ATCC strain was combined with PK models without covariates and with covariates (weight on V1 CMS or CL CR on CL CMS ) 5, 6 to generate new individuals by stochastic simulations. When covariate relationships were included in the simulation and estimations, the relationships were as suggested earlier: [C ss,ave target (average steady-state plasma concentration2 total concentration) was set at 1.5 mg/L to obtain similar colistin C ss as for a maintenance dose of 4.5 MU twice daily.]
A start inoculum of 4.5×10 5 cfu/mL, i.e. the average value of all starting inocula in the conducted experiments, was assumed in all simulations. The simulated medians and 5th and 95th percentiles for CMS concentration, colistin concentration and bacterial killing were computed at frequent timepoints during 36 h.
Software
Data were analysed using the Laplacian method and ADVAN9 within the population analysis software NONMEM7. 24 NONMEM was also used to simulate concentration -time and bacterial count -time profiles. Review of the dataset and graphical evaluation was performed with the Xpose program (version 4) 25 and R (version 2.10, www.r-project.org). Simulations and calculations for VPC, and execution of log-likelihood profiling, were performed using Perl speaks NONMEM (PsN) (version 3.5.5). 26 
Results
Measured colistin concentrations
The measured initial colistin concentrations in the experiments with P. aeruginosa ATCC 27853 were 0.042, 0.19, 0.3, 0.77, 2.2, 4.3 and 12 mg/L. In the P. aeruginosa ARU552 experiments, the initial colistin concentrations were 0.081, 0.25, 0.96, 2.7, 5.1, 11 and 24 mg/L. Except for the measured concentration of 24 mg/L, which was the same as the intended concentration, the measured colistin concentrations were 8.3% -83% lower than intended, with a larger loss the lower the concentration, and there was also a progressive decline in colistin concentration with time, probably due to unspecific binding of colistin to the material of the containers used and possible degradation during the experiments. The application of actual colistin concentrations was important in the characterization of the concentrationeffect relationship. As an example, using the measured concentration in the modelling increased the estimated E max for ATCC 27853 by 63% with only minor changes in EC 50 , and the slope value for ARU552 increased by 50%.
Time -kill curve experiments
There were 41 static experiments with a total of 821 data points (where 57 data timepoints entered in the dataset were below the LOD) in the data analysis. Time -kill curves for typical experiments are shown in Figure 2 . The bacteria exposed to no colistin or low concentrations of colistin were initially growing exponentially to asymptote, towards a maximum bacterial count of 10 9 cfu/mL. Initially, there appeared to be a small reduction in the number of bacteria in all experiments. For ATCC 27853 (Figure 2a) , regrowth occurred for concentrations of 0.042 -0.77 mg/L while the bacterial count remained below the LOD from 19 h for the concentration of 2.2 mg/L and from 3 h for concentrations of 4.3 and 12 mg/L. Regrowth occurred for all concentrations in the experiments for ARU552, and this strain appeared to be less susceptible than measured by Etest, where the MIC was only 50% higher than for the ATCC strain.
Semi-mechanistic PK/PD model
The model structure of the semi-mechanistic PK/PD model for gentamicin 5 could fairly well describe the effect of colistin when all parameters were allowed to be re-estimated. The influence of colistin in killing ATCC 27853 was best described by a basic E max model as there was no improvement in the fit (DOFV ¼ 0.9) when g was allowed to be estimated, while a linear model did not result in as good a fit. For ARU552, an E max model was not supported by the data and a linear function (g ¼ 1) was sufficient to describe the concentration -effect relationship. Attempts to apply the same E max parameter for the two strains resulted in a worse fit (OFV increased by 53 U) and therefore different functions were used. The observed emergence of adaptive resistance was best described as a reduced k col . The transfer rate constant (k on ) of non-resistance (Re OFF ) to resistance (Re ON ) was described by a sigmoid E max relationship for both strains (Equation 8). A reversal of resistance was estimated based on the current data using a firstorder rate constant, k off .
As indicated by the VPCs, the model described the observed data well for both strains of P. aeruginosa (Figure 3) . The parameter estimates of the final model are listed in Table 1 . The growth rate constants (k growth ) for the two strains were estimated at 0.919 and 0.813 h 21 for ATCC 27853 and ARU552, respectively, i.e. the growth rate was 11% lower for the clinical isolate from UAH. For ATCC 27853, colistin had a fast bactericidal effect with an initial maximum killing rate constant (E max ) of 282 h 21 and an EC 50 of 1.16 mg/L, i.e. at lower concentrations, where the concentration -effect relationship is linear, the slope (E max /EC 50 ) would be 243 L/mgh. The linear function for bacterial killing of ARU552 had an estimated slope of 15.9 L/mgh. At an unbound colistin concentration of 1 mg/L, the initial killing rate constant (k col ) would be 112 L/mgh for ATCC 27853 and 15.9 L/mgh for by a maintenance dose of 4.5 MU CMS (135 mg CBA) 12 hourly. Variability in only CMS parameters (d) and only colistin parameters (e) was simulated for the loading dose of 9 MU CMS. The black continuous line is the 50th percentile and the black broken lines represent the 5th and 95th percentiles. Grey broken lines represent the starting bacterial inoculum of 4.5×10 5 cfu/mL (top line), the 3 log kill (middle line) and 10 cfu/mL (bottom line). Note that unbound colistin concentrations are shown; for a typical unbound fraction of 0.34 the unbound concentrations should be multiplied by 2.9 to translate to total colistin concentrations.
Mohamed et al. Figure 5 . Simulated medians of CMS concentration (top panels), unbound colistin concentration (middle panels) and killing of the susceptible strain (ATCC 27853) (bottom panels) for a model not including covariate relationships (left panels) and a model including a covariate (right panels). The dosing algorithms presented by Garonzik et al. 6 were used to determine the doses in the simulations (except for the black continuous lines). In scenarios (a), (b) and (c), a flat fixed dose (9 MU CMS load; 4.5 MU CMS twice daily as maintenance) or the calculated doses based on Equations 10 and 11 for a weight-based loading dose (7 MU CMS, body weight 70 kg) and a CL CR maintenance dose (1.9, 3.4 and 5. The rate constants of natural bacterial death (k death ) and bacterial count in the stationary phase (B max ) were assumed to be the same for both strains. The rate constant for the bacteria to return to the susceptible state after developing resistance (k off ) was also set to have the same value for the two strains as there was no improvement in the fit when allowing them to be different. The rate of development of adaptive resistance was dependent on the colistin concentration as described by a sigmoid E max function, with a higher maximal achievable resistance rate constant (k onmax ) for ARU552 than for ATCC 27853 (4.76 versus 0.824 L/mgh), although the concentration needed to reach half of k onmax was much higher for ARU552 (105 mg/L) than for ATCC 27853 (2.61 mg/L). Colistin concentrations of 1, 12 and 24 mg/L resulted in predicted half-lives for onset of resistance of 2.6, 1.1 and 0.99 h, respectively, for ATCC 27853. For ARU552, the same concentrations were predicted to result in half-lives of 5.9, 0.96 and 0.61 h, respectively. The half-life for the bacteria to return to the susceptible state after developing adaptive resistance (ln2/k off ) was estimated to 7.6 h for both strains.
The alternative structural models tested did not fit the data equally well. The model with a compensatory mechanism for development of resistant bacteria had an OFV that was 164 U higher than when the final model was applied. When the resistance was modelled as a time-and concentration-dependent EC 50 , the OFV was 96 U higher. When a delay or a lag time function was fitted to account for the initial small reduction in the bacterial count there was no significant improvement in the OFV.
Simulations for assessment of variability
The simulations showed that the variability arising from IOV was higher than the variability arising from IIV for unbound colistin concentrations and also when propagated to variability in bacterial counts (Figure 4a -c) . For a loading dose of 6 MU CMS, 50% of the patients were predicted to achieve 3 log bacterial killing at 24 h, while for a 12 MU loading dose of CMS the majority of patients would have sufficient exposure for 3 log bacterial killing. The IIV and IOV in CMS parameters resulted in low variability in the colistin concentration and bacterial killing profiles ( Figure 4d ) compared with IIV and IOV in colistin parameters (Figure 4e ). The IIV for CMS resulted in lower colistin variability than IOV in CMS, and the same was found for colistin when only variability in colistin parameters was included in the simulations.
Simulations for comparison of dosing algorithms
For the model including a CL CR -CMS relationship (Figure 5a , right panel), log bacterial killing was clearly higher for the CL CR -based maintenance dosing for patients with reduced renal function (CL CR of 30 mL/min) compared with those with CL CR of 120 mL/min (3.0 versus 2.2) at 12 h for a flat fixed loading dose. A 24 h interval between loading and the initiation of maintenance dosing resulted in a tendency to regrowth of bacteria at 18 h for all loading doses tested (Figure 5b ). The CMS peak concentrations during maintenance dosing declined with infusion duration and were 14, 12 and 8 mg/L for a 15, 30 and 120 min infusion of 4.5 MU, but all evaluated infusion lengths resulted in similar colistin concentration and bacterial killing profiles (Figure 5c ). Body weight as a covariate on V1 for CMS had limited impact on the colistin concentrations, as seen when comparing the predictions for the model with (Figure 5d , right) and without (Figure 5d , left) body weight as a covariate. Importantly, a weight-based loading dose resulted in 2.7 less log bacterial killing at 24 h for a 50 kg compared with a 90 kg patient (Figure 5d ).
Discussion
In this study a mechanism-based PK/PD model that incorporates resistance development for colistin in two different strains of P. aeruginosa was developed. The model showed good ability to characterize the observed time courses of bacterial killing and colistin-driven adaptive resistance for a wide range of concentration -time profiles, as well as growth to a maximum number of bacteria in the system. k growth was found to be different for the two strains, the ATCC strain having a faster rate of growth. A specific value for k death could not be identified based on the data in the current study and a fixed value from a prior study 11 was assumed. The model maintained a similar structure for the adaptive resistance determined earlier for gentamicin in E. coli, 5 although here the degree of adaptive resistance characterized by Re ON directly affected the rate constant of drug effect. In addition, an E max function for the drug effect was not supported for ARU552, and a linear function was sufficient to describe the data.
Upon introduction of colistin into the in vitro environment there was a fast rate of bacterial killing. At the same time colistin triggered the development of adaptive resistance, which resulted in a graded reduction in the drug effect and thereby a reduced capacity to kill the bacteria. The presented model allows adaptive resistance to be reversible and to return to the original degree of susceptibility when colistin diminishes. The mechanism for temporary or adaptive resistance to colistin has been reported in several studies to involve the modification of lipid A of lipopolysaccharide (LPS) in the outer membrane of the bacterial cell wall. 27 -29 The responsible regulatory systems were indicated to be PhoP-PhoQ and PmrA-PmrB, which modify the net negative charge of LPS and reduce bacterial uptake of the antibiotic, 30, 31 although it has been shown that this mechanism was more relevant for Salmonella than for Pseudomonas. 29 Another regulatory system that has been proposed is ParR-ParS, which is required for modification of the operon in the presence of subinhibitory concentrations of polymyxin B and colistin. 28 The rate of onset of adaptive resistance to colistin was found to be lower compared with the rate characterized earlier for left panels, while in the right panels a CL CR -CMS CL relationship was included for scenarios (a) and (b), and a body weight -CMS V1 relationship was included in scenario (d). The calculated loading doses in scenario (d) were for weights of 50 kg (5 MU), 70 kg (7 MU), 90 kg (9 MU) or 120 kg (12 MU) and the maintenance dose was based on a CL CR of 70 mL/min (3.4 MU every 12 h). For scenario (c) only the results without inclusion of covariates are shown. In all flat fixed dose scenarios, a CL CR of 84 mL/min and a body weight of 70 kg were assumed. In the bottom panels (bacterial count), the grey broken lines represent the starting bacterial inoculum of 4.5×10 5 cfu/mL (top line), the 3 log kill (middle line) and 10 cfu/mL (bottom line).
gentamicin. 5 This may be because the time required to affect efflux pumps (the mechanism responsible for adaptive resistance to gentamicin) is shorter than that needed to affect LPS. Even though the colistin experiments were set up as a static study in which the antibiotic concentrations were intended to be constant throughout the experiment, colistin concentrations declined with time, as evidenced by the measured concentrations at 0, 8 and 24 h. The decreasing colistin concentrations seen in this study may have helped make it possible to estimate k off , despite the lack of dynamic experiments, and estimation of k off also allowed the degree of adaptive resistance to achieve equilibrium. In contrast, in the gentamicin study, nearly complete development of resistance was observed, and recovery from adaptive resistance (k off ) could not be identified during the study period.
A mechanistic PK/PD model has described the effect of colistin on the growth and killing of P. aeruginosa. 8 The model outlined a more detailed mechanism of action, with binding at target sites on LPS leading to bacterial killing and inhibition of drug effect by signal molecules. This mechanistic model structure required some parameters to be fixed during the estimation. The model included lag compartments, where bacteria do not replicate, and the effect of hypothetical signal molecules. Colistin was hypothesized to trigger the killing of three subpopulations of bacteria (susceptible, intermediate and resistant populations, each of which grows and dies naturally) at different rates, to explain resistance development. The model presented here explains resistance development as a gradual adaptation of the bacteria that would reverse upon drug removal, and was found to characterize the available data well (Figure 3 ).
In the current model, the regrowth observed was assumed to be due only to adaptive resistance. The current model structure may also be applicable when mutants with non-reversible resistance emerge during an experiment. In such cases the rate constant of the return of the bacteria to the susceptible state after developing resistance (k off ) would approach zero. In the presence of pre-existing subpopulations of resistant mutants, a model with different growth rates and/or sensitivities to drug exposure for two types of bacteria can explain the regrowth observed at the end of experiments. 8, 32 Simulations from the PK/PD model developed in this study provided an understanding of the relationship between clinically relevant time courses of antibiotic concentrations and the impact on bacterial killing. In combination with the previously developed PK model and a function for non-linear protein binding of colistin, 5 the model was used to generate unbound concentration -time profiles to drive the concentration -effect relationship. This allowed us to evaluate the effect of different dosing schedules and regimens, which can be useful in developing, adjusting and improving the clinical dosing guidelines. 33 The simulations showed the importance of a loading dose for rapid bacterial killing; at 12 h, 75% of the patients receiving a 12 MU loading dose of CMS achieved 3 log kill compared with 55% and 40% of those receiving 9 and 6 MU, respectively (Figure 4a -c, right panels) . Subinhibitory concentrations have been shown experimentally to be associated with bacterial regrowth and increased resistance, 28, 34 which further supports the use of a loading dose. The simulations utilized a PK model developed previously from data in critically ill patients, which incorporates IIV and IOV 5 for both CMS and colistin, and IOV was shown to impose a larger overall variability than IIV (Figure 4) . The large variability in bacterial killing appeared to be caused primarily by IOV in the formation of colistin and/or colistin clearance and the volume of distribution. These simulations suggest that target concentration dosing, where the dose to be administered is calculated using an algorithm based on covariates (e.g. weight, CL CR ), may overemphasize the value of individual dose adjustments. In the presence of a large IOV and/or a covariate that changes over time, covariatebased dose adjustment may be less useful to control variability, 35, 36 and flat fixed dosing may be a simpler alternative. A weight-based loading dose was shown to result in much lower bacterial killing in low-weight patients compared with patients weighing ≥70 kg (Figure 5d ). This is not surprising as the central volume of CMS has very limited impact on the time course of the active drug, colistin. A patient's CL CR value, however, already influences the degree of bacterial killing during the loading dose, with a greater extent of bacterial killing the lower the CL CR , assuming that a CL CMS -CL CR relationship exists (Figure 5a and b, right panels). This was also reflected after the maintenance dose, when CL CR -based dosing resulted in more similar profiles when the covariate relationship was assumed to be true and was included in the model for predictions of typical patients (Figure 5a and b) . The predictions also showed that an infusion duration of up to 2 h can be recommended based on the current simulations (Figure 5c ) as the bacterial killing profiles were similar for a 15 min, a 30 min and a 2 h infusion. There appeared to be some benefit in increasing the bacterial killing by introducing the maintenance dose before 24 h after the loading dose (compare Figure 5a and b) .
The PK/PD model developed here may be applied to other bacterial strains and species, and to other antibiotics, if the mechanisms of resistance are similar. However, parameter estimates are likely to vary, and some experimental data will be needed before applying the current model structure in different settings. It should also be recognized that the time -kill in vitro experiments that generated the data for the development of the PK/PD model were only conducted for a 24 h period and thus model extrapolations much beyond this time period should be made with caution. For example, de novo mutations may appear that are not characterized by the current model structure, and a hollow fibre system would be more suitable for the evaluation of longer treatment durations. In addition, the simulations were performed assuming that the bacteria are exposed to the same concentration -time profile as that predicted in the single distribution compartment of colistin. In a clinical situation the drug distribution may be delayed and the concentration magnitude may differ at the site of the infection, inoculum size will vary and the patient's immune system may contribute to bacterial killing. Our simulations therefore mimic a system without host defence and with a moderate bacterial load. However, we believe that the simulations add to the understanding of the impact of dosing regimen and variability for bacterial killing.
A clear advantage of applying a PK/PD model based on in vitro data in the development of dosing regimens, compared with the traditional PK/PD indices, is the ability to evaluate changes in the interaction of the drug and the bacteria over time (e.g. from 0 to 24 h). 37 Based on the semi-mechanistic model developed here, the outcome of new conditions, e.g. the evaluation of the time course of bacterial kill following a loading dose or time of initiation of maintenance dosing, was explored. Prediction of the effect of different inocula sizes could easily be predicted as well. 38 The PK/PD model for colistin and Pseudomonas aeruginosa
